Xing Xiangqin, Zhang Mei, Tan Shengfen, Zhu Junfeng, Li Jiajia, Zhang Pingping, Yuan Yuan, Wang Meng, Zhang Feng
Bengbu Medical University, Department of Hematology, Bengbu, P.R. China
The First Affiliated Hospital of Bengbu Medical University, Department of Hematology, Bengbu, P.R. China
Turk J Haematol. 2025 May 22;42(2):82-91. doi: 10.4274/tjh.galenos.2024.2025.0292. Epub 2025 Feb 17.
OBJECTIVE: Interferon-regulatory factor 2 (IRF2) and inositol polyphosphate 4-phosphatase B (INPP4B) are indispensable for differentiating immune T-cells, but the regulatory principle of the IRF2-INPP4B signaling channel in the apoptosis of acute myeloid leukemia (AML) cells remains unclear. This work investigates the function and regulatory principle of IRF2-INPP4B signaling in the progression of AML. MATERIALS AND METHODS: CD4 T-cells were extracted from peripheral blood and characterized via flow cytometry. Flow cytometry was used to estimate apoptosis in the HL60 AML cell line and determine the Th1/Th2 cell ratio. Quantitative real-time polymerase chain reaction was used to measure mRNA. Western blotting was performed to evaluate the protein levels of IRF2, INPP4B, JAK2, p-JAK2, STAT3, p-STAT3, and caspase 3. Interleukin-4 and interferon gamma concentrations were determined using enzyme-linked immunoadsorption assay kits. RESULTS: We discovered that levels of IRF2 and INPP4B were high in AML-derived CD4 T-cells. Furthermore, CD4 T-cells encouraged HL60 cell apoptosis. Downregulation of IRF2 encouraged HL60 cell apoptosis via alterations in the Th1/Th2 ratio while the overexpression of IRF2 stimulated the JAK2-STAT3 signaling channel and downregulated caspase 3. CONCLUSION: We revealed that IRF2-INPP4B signaling in CD4 T-cells stimulated the JAK2-STAT3 signaling channel and downregulated caspase 3, reducing AML cell apoptosis and aggravating AML progression. This work highlights an important regulatory principle concerning AML progression, as the IRF2-INPP4B pathway might impact the JAK2-STAT3 signaling channel. The findings contribute to our knowledge of the complicated interplay of these pathways in AML.
Turk J Haematol. 2025-5-22
J Exp Clin Cancer Res. 2018-1-17
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024-6
Signal Transduct Target Ther. 2024-10-9
J Allergy Clin Immunol. 2025-2
JAMA Oncol. 2024-10-1
Nat Immunol. 2024-5
Acta Haematol. 2024
Front Oncol. 2022-12-16